Omalizumab in children and adolescents with chronic urticaria: A 16-week real-world study

Allergy. 2021 Apr;76(4):1271-1273. doi: 10.1111/all.14686. Epub 2020 Dec 18.

Authors

Xiao-Ting Song^{1

2

3}, Yu-Di Chen⁴, Miao Yu^{1

2

3

5}, Bo Liu^{1

2

3}, Zuo-Tao Zhao^{1

2

3}, Marcus Maurer⁶

Affiliations

¹ Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
² Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
³ National Clinical Research Center for Skin and Immune Diseases, Beijing, China.
⁴ Department of Dermatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
⁵ Peking University School of Nursing, Beijing, China.
⁶ Department of Dermatology and Allergy, Charité - Universitätsmedizin, Berlin, Germany.

PMID: 33275779
DOI: 10.1111/all.14686

No abstract available

Keywords: immunotherapy clinical; pediatrics; quality-of-life; urticaria.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Anti-Allergic Agents* / therapeutic use
Child
Chronic Disease
Chronic Urticaria*
Humans
Omalizumab / therapeutic use
Treatment Outcome
Urticaria* / drug therapy

Substances

Anti-Allergic Agents
Omalizumab